InvestorsHub Logo
Followers 57
Posts 5697
Boards Moderated 0
Alias Born 12/13/2004

Re: None

Monday, 12/30/2019 12:51:54 PM

Monday, December 30, 2019 12:51:54 PM

Post# of 807
KP415 will compete with Takeda's Vyvanse which had double digit growth driven by higher demand....sales over $2.4 Billion in 2018. KemPharm CEO Mickle was the principal inventor of Vyvanse at New River before it was bought out for $2.6 Billion in 2007. What could KP415 annual revenues be? And what might a buyout price be for KemPharm's ADHD portfolio? Buehler? Anyone?

"The refusal of the real is the number one dogma of our time" Rene Girard

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KMPH News